Report
Autolus Aucatzyl r/r ALL data at ASH boosts positioning ahead of US launch
Autolus presented multiple datasets at ASH on Aucatzyl (CD19 CAR-T) in r/r adult ALL, which showed i) MRD response predicts EFS and OS outcomes with the largest MRD benefit seen in patients with lower tumour burden, ii) Aucatzyl's potential to lower healthcare costs with improved safety, iii) long term persistence for Aucatzyl regardless of bridging therapy, and iv) learnings from the FELIX trial. We believe the datasets further boost Aucatzyl's positioning ahead of the US launch in 2025, and reiterate our $ 11 TP and BUY rating.
Underlying
Autolus Therapeutics ADS
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Jacob Mekhael
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.